Quale sarebbe il prezzo per Ergomed plc (2EM)

Il prezzo per Ergomed plc (2EM) è $13.05

Qual è la capitalizzazione di mercato per Ergomed plc (2EM)

La capitalizzazione di mercato per Ergomed plc (2EM) è $695.07M

Ricavi di Ergomed plc (2EM)

Ergomed plc, alongside its affiliated entities, offers a comprehensive range of clinical trial services, encompassing planning, oversight, and execution, in addition to providing essential drug safety and medical information support. The company maintains an expansive global footprint, conducting operations throughout the United Kingdom, continental Europe, the Middle East, Africa, North America, Asia, and Australia. Its business is organized into two core divisions: Clinical Research Services and Pharmacovigilance. Ergomed assists pharmaceutical, biotechnology, and generic drug manufacturers by managing clinical development programs, facilitating post-market approval strategies, and delivering robust pharmacovigilance solutions. Their expertise is concentrated in several therapeutic domains, including oncology, haematology, allergy, respiratory, and neurology/CNS, with a notable specialization in the development of orphan drugs. Furthermore, they extend support services to clinical trial sites. Established in 1997, the organization originally traded as Ergomed Clinical Research Limited before rebranding as Ergomed plc in June 2014. Its corporate headquarters are situated in Guildford, United Kingdom.

Anno	Ricavi	Cambia
Non abbastanza dati per le date fornite.

Anno

Ricavi

Cambia

Non abbastanza dati per le date fornite.

Azienda	Ricavi	Differenza nei ricavi	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.74B	-	AU
Moderna, Inc. MRNA.US	$2.23B	-	US
Lonza Group AG LONN.SW	-	-	CH

Azienda

Ricavi

Differenza nei ricavi

Il paese